BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SomaGenics Inc. Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation National Institutes of Health (NIH) Grants


11/12/2012 11:07:19 AM

SANTA CRUZ, Calif., Nov. 12, 2012 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, has been awarded US Patent No. 8,283,460 for key aspects of the company's sshRNA therapeutic platform.  sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs through an RNA interference (RNAi) mechanism.  SomaGenics' lead therapeutic program targets hepatitis C, and a number of sshRNAs directed at the hepatitis C virus are covered by the new patent.  'This patent, following on the award of US Patent 7,902,351 in 2011, represents another significant milestone in securing comprehensive patent protection for our sshRNA technology," commented SomaGenics CEO Brian Johnston.

SomaGenics also announced the receipt of two Small Business Innovation Grants from the National Institutes of Health totaling $647,000.  One, from the National Institute of General Medical Sciences, is entitled Accelerating Wound Healing Using RNAi and aims to speed healing of the hard-to-heal wounds that can particularly plague diabetics.  Dr. Sumedha Jayasena, VP of Therapeutic Development at SomaGenics, is principal investigator.

A second grant, awarded by the National Cancer Institute, is entitled A Novel Method for Quantitation of Fragmented mRNAs.  Its goal is to develop a new approach to analyzing gene expression from formalin-fixed, paraffin-embedded (FFPE) tissue specimens. Large repositories of FFPE specimens, each with pathologist interpretation and clinical records, are available at many medical institutions.  The ability to determine gene expression profiles for each specimen could make these archives a rich resource for discovering mRNA biomarkers of disease. Although RT-qPCR is the preferred method for quantitative analysis of gene expression, its sensitivity and robustness are significantly reduced with FFPE samples due to the degradation of mRNAs that occurs during specimen preparation and storage. SomaGenics' mR-FQ RT-qPCR approach should overcome these problems because, unlike standard PCR methods, it is unaffected by fragmentation; indeed, it explicitly makes use of it. The principal investigator for this grant is Dr. Sergei Kazakov, VP of Discovery Research at SomaGenics.

The new awards bring SomaGenics' total grant funding to well over $18 million and allow the company to develop new applications for its technologies.

Contact:

Dr. Brian Johnston
CEO, SomaGenics, Inc.
www.somagenics.com
bjohnston@somagenics.com
831-426-7700 x12

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE SomaGenics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES